Please login to the form below

Not currently logged in
Email:
Password:

Ozurdex

This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer's Eylea in diabetic eye condition

NICE backs Bayer's Eylea in diabetic eye condition

NICE backs Bayer's Eylea in diabetic eye condition. TheInstitute also recommends Allergan's Ozurdex in final guidance. ... Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema (DMO).

Latest news

  • NICE recommends Ozurdex for diabetic eye condition NICE recommends Ozurdex for diabetic eye condition

    NICE recommends Ozurdex for diabetic eye condition. Draft guidance cites implant as option for patients with diabetic macular oedema. ... Ozurdex is injected into the eye once every six months and works by suppressing inflammation and preventing oedema

  • Fresh approval for Roche's Lucentis as competition heats up Fresh approval for Roche's Lucentis as competition heats up

    Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).

  • New eye indication for Allergan’s Ozurdex New eye indication for Allergan’s Ozurdex

    New eye indication for Allergan’ s Ozurdex. EU approval extends the drug's use to diabetic macular oedema. ... Ozurdex joins a competitive market for DMO, with approved drugs in the EU including Novartis' Lucentis (ranibizumab).

  • Allergan will start phase III DARPin trials next year Allergan will start phase III DARPin trials next year

    On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have

  • NICE against new indication for Novartis' Lucentis

    Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics